Elizabeth Yeu Lin - 13 Jun 2025 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Chief Medical Officer
Signature
/s/ Scott Sieckert, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
13 Jun 2025
Net transactions value
-$41,326
Form type
4
Filing time
17 Jun 2025, 16:07:05 UTC
Previous filing
07 Mar 2025
Next filing
20 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lin Elizabeth Yeu Chief Medical Officer C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE /s/ Scott Sieckert, Attorney-in-Fact 17 Jun 2025 0001842190

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Options Exercise +3,350 +63% 8,700 13 Jun 2025 Direct F1
transaction TARS Common Stock Sale $41,326 -1,006 -12% $41.08 7,694 16 Jun 2025 Direct F2
holding TARS Common Stock 15,866 13 Jun 2025 By Spouse's Roth IRA
holding TARS Common Stock 12,040 13 Jun 2025 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Restricted Stock Units Options Exercise $0 -3,350 -100% $0.000000 0 13 Jun 2025 Common Stock 3,350 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
F2 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3 Each RSU represents a contingent right to receive one share of the Company's common stock.
F4 RSUs granted on June 13, 2024, in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.